Business Context and Reporting Period
This Form 8-K Current Report, dated December 3, 2014, details a corporate restructuring for CytoSorbents Corporation. The filing reports the completion of a Reincorporation Merger, changing the company's state of incorporation from Nevada to Delaware, and the execution of a reverse stock split.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure changes rather than operational financial performance.
Material Changes Versus Prior Period
- Reincorporation: CytoSorbents Corporation (Nevada) merged into CytoSorbents Corporation (Delaware). The Nevada entity ceased to exist, and the Delaware entity became the surviving corporation.
- Reverse Stock Split: A 25-for-1 reverse stock split was effected immediately prior to the merger. Fractional shares were rounded up to the next whole share.
- Authorized Shares:
- Common stock authorized shares reduced from 800,000,000 to 50,000,000.
- Preferred stock authorized shares reduced from 100,000,000 to 5,000,000.
- Share Conversion: Each share of Nevada common stock was converted into one share of Delaware common stock.
Guidance, Outlook, and Risks
- Trading Status: The company anticipates common stock will begin trading on a post-split basis at market open on or about December 5, 2014.
- NASDAQ Listing: The company has applied to list its stock on the NASDAQ Capital Market. Approval is subject to NASDAQ standards, and there is no assurance of approval.
- Tax Status: The merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
- Operational Continuity: The filing states the merger did not result in changes to headquarters, business, jobs, management, facilities, employees, benefit plans, assets, or liabilities (excluding merger costs).
Investor Verification Checklist
- Confirm the effective date of the 25-for-1 reverse stock split and the resulting share count.
- Verify the status of the NASDAQ Capital Market listing application.
- Review the Amended and Restated Certificate of Incorporation and Bylaws (Exhibits 3(i).4 and 3(ii).1) for new governance provisions.
- Monitor the stock ticker symbol and trading volume post-December 5, 2014, to ensure proper post-split trading.